G3T Therapeutics

G3T is developing assets in cardio-metabolic, metabolic and cardiovascular diseases, such as non-alcoholic steatohepatitis (NASH), obesity, diabetes, atherosclerosis, etc. We define our assets as genetically validated drug targets. We partner with pharmaceutical, biopharmaceutical and biotechnology companies on specific assets. We also enter into broad discovery-based partnerships related to specific disease states, such as diabetes or obesity. In addition, we can assist clients and partners by validating their own targets based on the G3T platform, and by identifying companion and complimentary diagnostics that may predict a better response to specific drugs.